» Articles » PMID: 23113523

Caregiver Placebo Effect for Dogs with Lameness from Osteoarthritis

Overview
Date 2012 Nov 2
PMID 23113523
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To document the caregiver placebo effect in owners and veterinarians of dogs with lameness from osteoarthritis.

Design: Prospective, randomized, double-blinded, placebo-controlled, multicenter clinical trial.

Animals: 58 dogs with lameness secondary to osteoarthritis.

Procedures: Dogs enrolled in the placebo arm of an FDA-approved study were evaluated to determine the relationship between subjective (caregiver responses) and objective (force platform gait analysis) patient outcome measures.

Results: A caregiver placebo effect for owners evaluating their dog's lameness occurred 39.7% of the time. A caregiver placebo effect occurred 44.8% of the time when veterinarians examined dogs for lameness at a walk, 44.8% of the time when veterinarians examined dogs for lameness at a trot, and 43.1% of the time when veterinarians evaluated dogs for signs of pain on palpation of the joint. This effect was significantly enhanced with time. Mean ground reaction forces (GRFs) remained unchanged for dogs during treatment with the placebo. Individually, of 58 dogs, 5 had GRFs that worsened by ≥ 5% over 42 days, 7 had GRFs that improved by ≥ 5% over 42 days, and 46 had GRFs that remained unchanged.

Conclusions And Clinical Relevance: A caregiver placebo effect was common in the evaluation of patient response to treatment for osteoarthritis by both pet owners and veterinarians. Force platform gait analysis was an unbiased outcome measure for dogs with lameness from osteoarthritis. A caregiver placebo effect should be considered when interpreting owner and veterinary reports of patient response to treatment.

Citing Articles

Efficacy and Safety of a Diet Enriched with EPA and DHA, Turmeric Extract and Hydrolysed Collagen in Management of Naturally Occurring Osteoarthritis in Cats: A Prospective, Randomised, Blinded, Placebo- and Time-Controlled Study.

Lefort-Holguin M, Delsart A, Otis C, Moreau M, Barbeau-Gregoire M, Mellet F Animals (Basel). 2024; 14(22).

PMID: 39595350 PMC: 11591455. DOI: 10.3390/ani14223298.


Efficacy of a Single Injection of Stromal Vascular Fraction in Dogs with Elbow Osteoarthritis: A Clinical Prospective Study.

Bruns Y, Schroers M, Steigmeier-Raith S, Waselau A, Reese S, Meyer-Lindenberg A Animals (Basel). 2024; 14(19).

PMID: 39409752 PMC: 11475770. DOI: 10.3390/ani14192803.


Evaluation of the effect of cannabidiol administration with and without nonsteroidal anti-inflammatory drugs in dogs with mobility disorders: a prospective, double-blind, crossover, placebo-controlled study.

Talsma B, Elam L, McGrath S, Zhou T, Webb C, Duerr F Front Vet Sci. 2024; 11:1449343.

PMID: 39386246 PMC: 11461463. DOI: 10.3389/fvets.2024.1449343.


The oral intake of specific Bioactive Collagen Peptides (BCP) improves gait and quality of life in canine osteoarthritis patients-A translational large animal model for a nutritional therapy option.

Dobenecker B, Boswald L, Reese S, Steigmeier-Raith S, Trillig L, Oesser S PLoS One. 2024; 19(9):e0308378.

PMID: 39298537 PMC: 11412516. DOI: 10.1371/journal.pone.0308378.


Client-based evaluation of the effects of localized vibration therapy on pain and mobility scores in dogs with radiographic bilateral hip dysplasia.

Turner K, Canapp Jr S, Canapp D, Sutton A, Canapp A, Jimenez I Front Vet Sci. 2024; 11:1424373.

PMID: 39234179 PMC: 11373568. DOI: 10.3389/fvets.2024.1424373.